S1300: A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit From Crizotinib Monotherapy
Phase of Trial: Phase II
Latest Information Update: 02 May 2019
Price : $35 *
At a glance
- Drugs Crizotinib (Primary) ; Pemetrexed
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Dec 2018 Status changed from suspended to discontinued.
- 31 Aug 2018 Biomarkers information updated
- 06 Dec 2017 Status changed from recruiting to suspended.